Previous 10 | Next 10 |
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2023 / Halberd Corporation (OTC PINK:HALB) . During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to...
JACKSON CENTER, PA / ACCESSWIRE / May 31, 2023 / Halberd Corporation (OTC PINK:HALB) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University...
MSU is ahead of schedule and continues testing program JACKSON CENTER, PA / ACCESSWIRE / May 23, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and stu...
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB ) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol...
Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention...
CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment. JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman an...
Reason for correction - to correct percentages from rounded figures to more accurate actual numbers. Boosts effectiveness by 44.4% of commercially available Covid antibody in cocktail JACKSON CENTER, PA / ACCESSWIRE / December 1, 2022 / Halberd Corporation's (OTC-PINK: HALB ) Covid rese...
Boosts effectiveness by 50% of commercially available Covid antibody in cocktail JACKSON CENTER, PA / ACCESSWIRE / November 30, 2022 / Halberd Corporation's (OTC PINK:HALB) Covid research has led to a scientific article titled, " A Novel Plant-Made Monoclonal Antibody Enhances the Synerget...
Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date. JACKSON CENTER, PA / ACCESSWIRE / November 17, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have been successful in in-vitro laboratory tests using buffer sol...
* Accelerated Sales of HALB's Patented Products through newly formed "The Hamden Group" . JACKSON CENTER, PA / ACCESSWIRE / November 14, 2022 / Halberd Corporation (OTC-PINK:HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists...
News, Short Squeeze, Breakout and More Instantly...
Walt Disney once said, "All our dreams can come true if we have the courage to pursue them". JACKSON CENTER, PA / ACCESSWIRE / May 22, 2024 / Halberd Corporation (OTC PINK:HALB) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues ...
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the treatment and mitigation of the negative ...
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to...